sorafenib has been researched along with colchicine in 10 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (colchicine) | Trials (colchicine) | Recent Studies (post-2010) (colchicine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 15,472 | 404 | 2,974 |
| Protein | Taxonomy | sorafenib (IC50) | colchicine (IC50) |
|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | 3.7639 | |
| Tubulin beta chain | Sus scrofa (pig) | 3.8663 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta chain | Homo sapiens (human) | 2.7244 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 2.4334 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 4.3 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 2.4334 | |
| Vesicular acetylcholine transporter | Tetronarce californica (Pacific electric ray) | 2.62 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.8255 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 2.4334 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.0611 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.1553 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 2.4334 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| El-Ashmawy, MB; El-Gohary, NS; Shehata, IA; Warda, ET | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Al-Ach, NN; Al-Tel, TH; Alshihabi, AM; Anbar, HS; El-Awady, R; El-Gamal, MI; El-Gamal, R; Kalla, RR; Munther, MA; Sbenati, RM; Shahin, AI; Shehata, MK; Tarazi, H; Tokatly, RT; Wahba, MM; Zaraei, SO | 1 |
| Garg, P; Shaikh, N; Sharma, M | 1 |
| Awad, SM; El-Hameed, RHA; Khodair, MAE; Mohamed, MS | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
2 review(s) available for sorafenib and colchicine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
1 trial(s) available for sorafenib and colchicine
| Article | Year |
|---|---|
Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cholestasis; Colchicine; Diarrhea; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Sorafenib; Treatment Outcome | 2021 |
7 other study(ies) available for sorafenib and colchicine
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Topics: Apoptosis; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydroxyquinolines; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinolines; Sorafenib; Structure-Activity Relationship | 2022 |
An improved approach for predicting drug-target interaction: proteochemometrics to molecular docking.
Topics: Aldehyde Reductase; Anthracyclines; Antineoplastic Agents; Colchicine; Databases, Protein; Demecolcine; Drug Interactions; Models, Biological; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Proteomics; Reproducibility of Results; Sorafenib; Support Vector Machine | 2016 |
Synthesis and Evaluation of Cytotoxic Activity of Certain Benzo[h]chromene Derivatives.
Topics: Antineoplastic Agents; Benzopyrans; Cell Proliferation; Cell Survival; Colchicine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Tubulin Modulators | 2021 |
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colchicine; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2022 |